Let it slip a few notches as far as I'm concerned. LXGTF probably doesn't have much to PR about while waiting for the clinical trials to conclude. This gives it a breather and if it slips a bit it's just a chance for investors to pick up a few discounts before they announce verified FDA clearance. When they announce that it's at least a double bagger from this level.
News 
Market Data 
Discover 
